On September 25, Beijing CytoNiche Biotechnology Co., Ltd. (hereinafter referred to as CytoNiche) and Beijing Beilai Biosciences Co. Ltd. (hereinafter referred to as Beilai Biosciences) formed an in-depth strategic cooperation partnership based on the concept of strong alliances and innovative development, and jointly signed a strategic cooperation agreement.

Professor Du Yanan, chief scientist of CytoNiche, Dr. Liu Wei, CEO of CytoNiche, Dr. Sun Yanxun, Director of the Cell Transformation Research Center of CytoNiche, Dr. Liu Yongjun, Chairman of Beilai Biosciences, and Dr. Liu Guangyang, R&D Director of Beilai Biosciences, attended the signing ceremony.

The two parties will collaborate on the development of stem cell-related technologies and the clinical translational application of their products in the fields of 3D micro-tissue engineering technology, large-scale stem cell culture and expansion process, and stem cell micro-tissue new drug development.

CytoNiche is a high-tech company specializing in the research and development of interdisciplinary cutting-edge disciplines such as tissue engineering, biomaterials, cell biology, and regenerative medicine. It is a high-tech enterprise with core intellectual property rights in the fields of material microprocessing technology, 3D cultures of stem cells, and regenerative treatment technology.Based on the core technology of 3D TableTrix® Microcarrier Tablet, CytoNiche has established an automated, large-scale and customized cell preparation process through its proprietary 3D FloTrix® series of bioreactors and relevant products, which solves the technical difficulties in the development of cell industrialization such as high cost of cell preparation, low batch yield, inconsistent quality, and the inability to achieve standardized operations, so as to realize the "intelligent manufacturing" of large-scale and standardized production of cell therapy products.The company has independently developed more than 20 genetically modified stem cell products for solid tumors, forming a combinational therapy system for solid tumors, and has technical advantages as well as an independent intellectual properties system in this field.

Beilai Biosciences is a high-tech enterprise focusing on the research of stem cell and regenerative medicine as well as new drug development and clinical transformation of stem cells.Up to now,the company is committed to the new drug development and clinical research of stem cells. At present, two types of "Human Umbilical Cord Mesenchymal Stem Cell Injections" have been approved for the investigational drug application by the National Medical Products Administration to enter clinical trials.

After the signing ceremony, the "Regenerative Medicine and Clinical Application Seminar" hosted by Tsinghua University and undertaken by Beijing CytoNiche Biotechnology Co., Ltd. was held in Huairou Yanqi Hotel.